Venetoclax in Previously Treated Waldenström Macroglobulinemia

Jorge J. Castillo; John N. Allan; Tanya Siddiqi; Ranjana H. Advani; Kirsten Meid; Carly Leventoff; Timothy P White; Catherine A Flynn; Shayna Sarosiek; Andrew R. Branagan; Richard R. Furman; Steven P. Treon

doi:https://doi.org/10.1200/jco.21.01194

doi.org/10.1200/jco.21.01194

Venetoclax in Previously Treated Waldenström Macroglobulinemia

,

,

..., Steven P. Treon

80

Journal of Clinical Oncology45.30

Published: Nov 18, 2021

Abstract

PURPOSEBCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenstrom macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in...

Paper Fields

Paper Details

Title

Venetoclax in Previously Treated Waldenström Macroglobulinemia

DOI

doi.org/10.1200/jco.21.01194

Published Date

Nov 18, 2021

Journal

Journal of Clinical Oncology

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History